Hongqin You , Yixin Wang , Xiaokun Wang , Huifang Zhu , Yajie Zhao , Peng Qin , Xue Liu , Mengyu Zhang , Xiaomin Fu , Benling Xu , Yong Zhang , Zibing Wang , Quanli Gao
{"title":"CD69+ Vδ1γδ T 细胞是肝细胞癌的抗肿瘤亚群。","authors":"Hongqin You , Yixin Wang , Xiaokun Wang , Huifang Zhu , Yajie Zhao , Peng Qin , Xue Liu , Mengyu Zhang , Xiaomin Fu , Benling Xu , Yong Zhang , Zibing Wang , Quanli Gao","doi":"10.1016/j.molimm.2024.06.006","DOIUrl":null,"url":null,"abstract":"<div><h3>Background & aims</h3><p>Hepatocellular carcinoma (HCC), one of the malignancies with a wide expression of stress ligands recognized by Vδ1γδ T cells, has received much attention in adoptive immunotherapy of γδ T cells. In this study, we aimed to identify the potential anti-tumor Vδ1γδ T subpopulations in HCC.</p></div><div><h3>Methods</h3><p>Healthy donors (HDs) and HCC patients were recruited from the Affiliated Cancer Hospital of Zhengzhou University. Blood and tumor tissue samples were obtained respectively. Bioinformatics methods were used to analyze total γδ T cells and subsets infiltration, overall survival of HCC patients with high and low infiltration level of Vδ1γδ T cells, and <em>IFNG</em>, <em>granzyme A, granzyme B and perforin</em> expression in <em>TRDV1</em><sup>high/low</sup><em>CD69</em><sup>high/low</sup> groups. CD69 expression and Vδ1γδT cells infiltration in HCC were detected by immunofluorescence. Phenotypic analysis of Vδ1γδ T cells in blood and tumor tissue samples were performed by flow cytometry.</p></div><div><h3>Results</h3><p>Vδ1γδ T cells infiltrating in HCC were associated with better clinical outcome. Study in tumor micro-environment (TME) of HCC demonstrated that not total Vδ1γδ T but CD69<sup>+</sup> Vδ1γδ subset infiltration was associated with smaller tumor volume. Moreover, HCC patients simultaneously with high <em>TRDV1</em> and <em>CD69</em> expression produced more effector molecules and had longer survival time. Since Vδ1γδ T cells in the tumor microenvironment were often difficult to access, we demonstrated that CD69<sup>+</sup> Vδ1γδ T cells also existed in peripheral blood mononuclear cells (PBMC) of HCC and displayed enhanced cytotoxic potentials than HDs. Finally, we investigated the functions and found that CD69<sup>+</sup> Vδ1γδ T cells exhibited stronger tumor reactivities when challenged by tumor cells.</p></div><div><h3>Conclusions</h3><p>CD69<sup>+</sup> Vδ1γδ T cells are functional Vδ1γδ T cell subsets in patients with HCC. Circulating CD69<sup>+</sup> Vδ1γδ T cell is a promising candidate in immunotherapy of HCC.</p></div>","PeriodicalId":18938,"journal":{"name":"Molecular immunology","volume":"172 ","pages":"Pages 76-84"},"PeriodicalIF":3.2000,"publicationDate":"2024-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"CD69+ Vδ1γδ T cells are anti-tumor subpopulations in hepatocellular carcinoma\",\"authors\":\"Hongqin You , Yixin Wang , Xiaokun Wang , Huifang Zhu , Yajie Zhao , Peng Qin , Xue Liu , Mengyu Zhang , Xiaomin Fu , Benling Xu , Yong Zhang , Zibing Wang , Quanli Gao\",\"doi\":\"10.1016/j.molimm.2024.06.006\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background & aims</h3><p>Hepatocellular carcinoma (HCC), one of the malignancies with a wide expression of stress ligands recognized by Vδ1γδ T cells, has received much attention in adoptive immunotherapy of γδ T cells. In this study, we aimed to identify the potential anti-tumor Vδ1γδ T subpopulations in HCC.</p></div><div><h3>Methods</h3><p>Healthy donors (HDs) and HCC patients were recruited from the Affiliated Cancer Hospital of Zhengzhou University. Blood and tumor tissue samples were obtained respectively. Bioinformatics methods were used to analyze total γδ T cells and subsets infiltration, overall survival of HCC patients with high and low infiltration level of Vδ1γδ T cells, and <em>IFNG</em>, <em>granzyme A, granzyme B and perforin</em> expression in <em>TRDV1</em><sup>high/low</sup><em>CD69</em><sup>high/low</sup> groups. CD69 expression and Vδ1γδT cells infiltration in HCC were detected by immunofluorescence. Phenotypic analysis of Vδ1γδ T cells in blood and tumor tissue samples were performed by flow cytometry.</p></div><div><h3>Results</h3><p>Vδ1γδ T cells infiltrating in HCC were associated with better clinical outcome. Study in tumor micro-environment (TME) of HCC demonstrated that not total Vδ1γδ T but CD69<sup>+</sup> Vδ1γδ subset infiltration was associated with smaller tumor volume. Moreover, HCC patients simultaneously with high <em>TRDV1</em> and <em>CD69</em> expression produced more effector molecules and had longer survival time. Since Vδ1γδ T cells in the tumor microenvironment were often difficult to access, we demonstrated that CD69<sup>+</sup> Vδ1γδ T cells also existed in peripheral blood mononuclear cells (PBMC) of HCC and displayed enhanced cytotoxic potentials than HDs. Finally, we investigated the functions and found that CD69<sup>+</sup> Vδ1γδ T cells exhibited stronger tumor reactivities when challenged by tumor cells.</p></div><div><h3>Conclusions</h3><p>CD69<sup>+</sup> Vδ1γδ T cells are functional Vδ1γδ T cell subsets in patients with HCC. Circulating CD69<sup>+</sup> Vδ1γδ T cell is a promising candidate in immunotherapy of HCC.</p></div>\",\"PeriodicalId\":18938,\"journal\":{\"name\":\"Molecular immunology\",\"volume\":\"172 \",\"pages\":\"Pages 76-84\"},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2024-06-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Molecular immunology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0161589024001160\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular immunology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0161589024001160","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景与目的:肝细胞癌(HCC)是Vδ1γδ T细胞识别的应激配体广泛表达的恶性肿瘤之一,在γδ T细胞的采用性免疫疗法中备受关注。本研究旨在鉴定 HCC 中潜在的抗肿瘤 Vδ1γδ T 亚群。分别采集血液和肿瘤组织样本。采用生物信息学方法分析TRDV1高/低CD69高/低组的γδT细胞总数和亚群浸润情况、Vδ1γδT细胞高浸润组和低浸润组HCC患者的总生存率,以及IFNG、粒酶A、粒酶B和穿孔素的表达情况。免疫荧光检测了 CD69 表达和 Vδ1γδT 细胞在 HCC 中的浸润。流式细胞术对血液和肿瘤组织样本中的 Vδ1γδ T 细胞进行了表型分析:结果:浸润 HCC 的 Vδ1γδ T 细胞与更好的临床预后相关。对 HCC 肿瘤微环境(TME)的研究表明,不是全部 Vδ1γδ T 细胞,而是 CD69+ Vδ1γδ 亚群浸润与较小的肿瘤体积有关。此外,同时具有 TRDV1 和 CD69 高表达的 HCC 患者产生的效应分子更多,生存时间更长。由于肿瘤微环境中的 Vδ1γδ T 细胞通常难以获得,我们证明了 CD69+ Vδ1γδ T 细胞也存在于 HCC 患者的外周血单核细胞(PBMC)中,并且显示出比 HDs 更强的细胞毒性潜能。最后,我们对其功能进行了研究,发现 CD69+ Vδ1γδ T 细胞在受到肿瘤细胞挑战时表现出更强的肿瘤反应性:结论:CD69+ Vδ1γδ T 细胞是 HCC 患者的功能性 Vδ1γδ T 细胞亚群。循环中的 CD69+ Vδ1γδ T 细胞是 HCC 免疫疗法中一个有希望的候选细胞。
CD69+ Vδ1γδ T cells are anti-tumor subpopulations in hepatocellular carcinoma
Background & aims
Hepatocellular carcinoma (HCC), one of the malignancies with a wide expression of stress ligands recognized by Vδ1γδ T cells, has received much attention in adoptive immunotherapy of γδ T cells. In this study, we aimed to identify the potential anti-tumor Vδ1γδ T subpopulations in HCC.
Methods
Healthy donors (HDs) and HCC patients were recruited from the Affiliated Cancer Hospital of Zhengzhou University. Blood and tumor tissue samples were obtained respectively. Bioinformatics methods were used to analyze total γδ T cells and subsets infiltration, overall survival of HCC patients with high and low infiltration level of Vδ1γδ T cells, and IFNG, granzyme A, granzyme B and perforin expression in TRDV1high/lowCD69high/low groups. CD69 expression and Vδ1γδT cells infiltration in HCC were detected by immunofluorescence. Phenotypic analysis of Vδ1γδ T cells in blood and tumor tissue samples were performed by flow cytometry.
Results
Vδ1γδ T cells infiltrating in HCC were associated with better clinical outcome. Study in tumor micro-environment (TME) of HCC demonstrated that not total Vδ1γδ T but CD69+ Vδ1γδ subset infiltration was associated with smaller tumor volume. Moreover, HCC patients simultaneously with high TRDV1 and CD69 expression produced more effector molecules and had longer survival time. Since Vδ1γδ T cells in the tumor microenvironment were often difficult to access, we demonstrated that CD69+ Vδ1γδ T cells also existed in peripheral blood mononuclear cells (PBMC) of HCC and displayed enhanced cytotoxic potentials than HDs. Finally, we investigated the functions and found that CD69+ Vδ1γδ T cells exhibited stronger tumor reactivities when challenged by tumor cells.
Conclusions
CD69+ Vδ1γδ T cells are functional Vδ1γδ T cell subsets in patients with HCC. Circulating CD69+ Vδ1γδ T cell is a promising candidate in immunotherapy of HCC.
期刊介绍:
Molecular Immunology publishes original articles, reviews and commentaries on all areas of immunology, with a particular focus on description of cellular, biochemical or genetic mechanisms underlying immunological phenomena. Studies on all model organisms, from invertebrates to humans, are suitable. Examples include, but are not restricted to:
Infection, autoimmunity, transplantation, immunodeficiencies, inflammation and tumor immunology
Mechanisms of induction, regulation and termination of innate and adaptive immunity
Intercellular communication, cooperation and regulation
Intracellular mechanisms of immunity (endocytosis, protein trafficking, pathogen recognition, antigen presentation, etc)
Mechanisms of action of the cells and molecules of the immune system
Structural analysis
Development of the immune system
Comparative immunology and evolution of the immune system
"Omics" studies and bioinformatics
Vaccines, biotechnology and therapeutic manipulation of the immune system (therapeutic antibodies, cytokines, cellular therapies, etc)
Technical developments.